Manzano Sagrario, Agüera Luis, Aguilar Miquel, Olazarán Javier
Department of Neurology, Infanta Leonor Hospital, Madrid, Spain.
Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain.
Front Neurol. 2020 Jul 7;11:614. doi: 10.3389/fneur.2020.00614. eCollection 2020.
Alzheimer's disease (AD) is the most prevalent neurodegenerative condition, especially among elderly people. The presence of cortical β-amyloid deposition, together with tau phosphorylation and intracellular accumulation of neurofibrillary tangles (NFT) is the main neuropathologic criteria for AD diagnosis. Additionally, a role of inflammatory, mitochondrial, and metabolic factors has been suggested. Tramiprosate binds to soluble amyloid, thus inhibiting its aggregation in the brain. It reduced oligomeric and fibrillar (plaque) amyloid, diminished hippocampal atrophy, improved cholinergic transmission, and stabilized cognition in preclinical and clinical studies. In this narrative review, current information on the efficacy and safety of tramiprosate, both in AD and in other neurocognitive disorders, is presented. Possible directions for future studies with tramiprosate are also discussed.
阿尔茨海默病（AD）是最常见的神经退行性疾病，在老年人中尤为普遍。皮质β-淀粉样蛋白沉积的存在，以及tau蛋白磷酸化和神经原纤维缠结（NFT）的细胞内积聚是AD诊断的主要神经病理学标准。此外，炎症、线粒体和代谢因素也被认为发挥了作用。曲美普明与可溶性淀粉样蛋白结合，从而抑制其在大脑中的聚集。在临床前和临床研究中，它减少了寡聚和纤维状（斑块）淀粉样蛋白，减轻了海马萎缩，改善了胆碱能传递，并稳定了认知功能。在这篇叙述性综述中，介绍了曲美普明在AD和其他神经认知障碍中的疗效和安全性的当前信息。还讨论了曲美普明未来研究的可能方向。
